Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI(Rx) in Patients With ESRD

INTRODUCTION: Patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) have an increased risk of thrombotic events and bleeding. Antisense reduction of factor XI (FXI) with IONIS-FXI(Rx) is a novel strategy that may safely reduce the risk of thrombotic events. METHODS: This multicent...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Michael, Bethune, Claudette, Smyth, Andrew, Tyrwhitt, Jessica, Jung, Shiangtung W., Yu, Rosie Z., Wang, Yanfeng, Geary, Richard S., Weitz, Jeffrey, Bhanot, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820988/
https://www.ncbi.nlm.nih.gov/pubmed/35155859
http://dx.doi.org/10.1016/j.ekir.2021.11.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820988/
https://www.ncbi.nlm.nih.gov/pubmed/35155859
http://dx.doi.org/10.1016/j.ekir.2021.11.011

Ejemplares similares